Ona Therapeutics
Summary active Updated Jun 3, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Ona Therapeutics is a Barcelona-based biopharmaceutical company developing first-in-class antibody-drug conjugates (ADCs) for treatment-resistant cancers 1 2. The company is based at the Barcelona Science Park and was spun out of IRB Barcelona and ICREA 1. Its patient-driven discovery platform identifies novel tumor-specific antigens associated with resistance biology.
Series B proceeds will advance ONA-255, a first-in-class ADC initially focused on breast cancer, into clinical development, and progress ONA-389, a second first-in-class ADC targeting colorectal cancer. The company is also expanding indications into gastric and liver cancer 1 2.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-04 | Series B | $86.6M | Columbus Venture Partners, Mérieux Equity Partners | COFIDES, Korys, Alta Life Sciences, Asabys Partners, Bpifrance, CDTI, FundPlus NV, Ysios Capital 1 2 3 |
What Investors Say
No independently sourced investor quotes found at this time.
What Founders Say
No independently sourced founder quotes found at this time.
Sources
-
“Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development,” GlobeNewswire, June 4, 2026. https://www.globenewswire.com/news-release/2026/06/04/3306533/0/en/ona-therapeutics-raises-86-6-million-series-b-to-advance-first-in-class-adcs-into-clinical-development.html↩↩↩↩
-
“Ona Therapeutics Raises $86.6 Million Series B,” BioSpace, June 4, 2026. https://www.biospace.com/press-releases/ona-therapeutics-raises-86-6-million-series-b-to-advance-first-in-class-adcs-into-clinical-development↩↩↩
-
“ADC biotech Ona Therapeutics secures $86.6M in Series B raise,” Endpoints News, June 4, 2026. https://endpoints.news/adc-biotech-ona-therapeutics-secures-86-6m-in-series-b-raise/↩